Officials said the Ebola epidemic in the Democratic Republic of Congo had become the world's second-largest outbreak and was spreading at an unprecedented pace. They urged greater international attention to contain it.
12:52 PMAl Jazeera24 stories from 11 sources
Outbreaks surge as healthcare systems face pressure and setbacks
Day’s Recap
Supporting Articles
The health update reports that the nominee to lead the CDC is advancing to a full Senate vote, while Medicaid work requirements will proceed without delay. It also points to potential federal improvements in infectious disease monitoring.
8:28 AMStat News
Rare disease advocates warn that new Medicaid work requirements could cause patients and caregivers to lose coverage, even when illness limits their ability to work or complete administrative tasks. They are advising affected families to prepare for the changes.
7:00 AMCNBC
Republican candidates who supported the One Big Beautiful Bill Act are airing ads that portray them as advocates for lower healthcare costs. The campaign comes after the law reduced federal healthcare funding.
5:00 AMNPR Politics
New York City health officials declared the Upper East Side Legionnaires’ disease outbreak over after the two-week incubation period for linked cases passed. The outbreak killed seven people, and officials said no further cases tied to the cluster had emerged.
2:56 PMThe City
Novo Nordisk shares fell sharply after the Danish healthcare company reported that a Phase 3 trial had failed.
9:54 AMMarketWatch
A Novo Nordisk drug failed to meet its goal in a heart disease study, raising doubts about whether targeting inflammation can prevent cardiovascular complications.
8:32 AMStat NewsEuropean shares gave back Friday's gains after Novo Nordisk fell on a failed drug study and Universal Music Group dropped to a record low following disappointing earnings.
3:21 AMBloomberg Markets
A shortage of CT scanners in Gaza is delaying diagnostic examinations and worsening the medical crisis. Patients face longer waits for information needed to identify injuries and guide treatment.
8:55 AMAl Jazeera
The Trump administration revised its planned rebate pilot for the 340B drug discount program, prompting opposition from hospitals. The changes move the pilot toward implementation while preserving a model that providers say could impose significant administrative burdens.
1:02 PMStat News12:52 PMAl Jazeera
DR Congo Ebola epidemic becomes world’s second largest outbreak
Summary
Officials said the Ebola epidemic in the Democratic Republic of Congo had become the world's second-largest outbreak and was spreading at an unprecedented pace. They urged greater international attention to contain it.
The outbreak's rapid expansion indicates that local response capacity is being outpaced by transmission, logistics,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A rapidly expanding Ebola outbreak raises the risk of wider regional transmission and exposes the consequences of delayed global mobilization.
2 stories · 2 sources
8:28 AMStat News
Federal government could improve infectious disease monitoring, says federal government
Summary
The health update reports that the nominee to lead the CDC is advancing to a full Senate vote, while Medicaid work requirements will proceed without delay. It also points to potential federal improvements in infectious disease monitoring.
The immediate policy shift is that both CDC leadership and Medicaid implementation are moving forward
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Federal decisions on CDC leadership, Medicaid access, and disease surveillance could simultaneously affect outbreak preparedness and healthcare coverage.
7:00 AMCNBC
New Medicaid work rules could cause patients to lose coverage, rare disease advocates warn
Summary
Rare disease advocates warn that new Medicaid work requirements could cause patients and caregivers to lose coverage, even when illness limits their ability to work or complete administrative tasks. They are advising affected families to prepare for the changes.
The main risk is procedural as much as medical: eligible patients could lose coverage because
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Coverage interruptions can quickly disrupt specialist care, medicines and services that rare disease patients cannot easily replace.
5:00 AMNPR Politics
Ahead of midterms, Republicans run ads after cutting healthcare funds
Summary
Republican candidates who supported the One Big Beautiful Bill Act are airing ads that portray them as advocates for lower healthcare costs. The campaign comes after the law reduced federal healthcare funding.
Republicans are trying to reframe a record of reducing federal healthcare support as a promise
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Healthcare gives Democrats a direct way to tie Republican votes on the bill to household costs in competitive races.
2:56 PMThe City
Upper East Side Legionnaires’ Outbreak is Quelled, Health Commissioner Says
Summary
New York City health officials declared the Upper East Side Legionnaires’ disease outbreak over after the two-week incubation period for linked cases passed. The outbreak killed seven people, and officials said no further cases tied to the cluster had emerged.
The immediate public-health threat has ended, but the death toll leaves questions about how the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The outbreak is contained, but its causes and the adequacy of local building-safety oversight remain consequential.
3 stories · 3 sources
9:54 AMMarketWatch
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
Summary
Novo Nordisk shares fell sharply after the Danish healthcare company reported that a Phase 3 trial had failed.
The failed study adds another setback to Novo Nordisk's effort to sustain growth beyond its
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The result puts pressure on Novo Nordisk's future growth strategy, not just its share price.
2 stories · 2 sources
8:32 AMStat News
STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
Summary
A Novo Nordisk drug failed to meet its goal in a heart disease study, raising doubts about whether targeting inflammation can prevent cardiovascular complications.
The result weakens the case for this specific anti-inflammatory approach in cardiovascular prevention and adds
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The failed study challenges a promising strategy for preventing cardiovascular disease and narrows Novo Nordisk's pipeline options.
3:21 AMBloomberg Markets
European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump
Summary
European shares gave back Friday's gains after Novo Nordisk fell on a failed drug study and Universal Music Group dropped to a record low following disappointing earnings.
Novo Nordisk's setback weakened both the company and the broader healthcare sector, helping erase part
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A clinical failure at one of Europe's biggest drugmakers is now affecting both sector sentiment and broader equity markets.
8:55 AMAl Jazeera
The waiting game: Gaza’s CT scan shortage causing worries and worse
Summary
A shortage of CT scanners in Gaza is delaying diagnostic examinations and worsening the medical crisis. Patients face longer waits for information needed to identify injuries and guide treatment.
The decisive constraint is the lack of functioning CT capacity, which turns diagnosis into a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The shortage is converting limited medical infrastructure into delayed diagnoses, preventable deterioration, and harder treatment decisions.
1:02 PMStat News
STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals
Summary
The Trump administration revised its planned rebate pilot for the 340B drug discount program, prompting opposition from hospitals. The changes move the pilot toward implementation while preserving a model that providers say could impose significant administrative burdens.
The revision does not settle the core conflict over who should manage and receive 340B
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The pilot could alter the financial mechanics of a major drug-discount program used by hospitals serving vulnerable patients.
Other Developments
A curated list of other prominent stories from this day.
Kush, a dangerous synthetic drug, is spreading across Liberia and leaving families to manage its social and health consequences. The people driving the trade remain largely beyond the reach of authorities.
11:18 PMAl Jazeera
A Senate hearing featuring Anthony Fauci revived the dispute over COVID-19's origins but produced little new evidence. The session reflected the partisan divide surrounding the issue and the influence of misleading claims from the White House.
6:10 PMAl JazeeraKKR is nearing an agreement worth more than $4 billion to acquire medical device maker Integer Holdings, which has also attracted attention from an activist hedge fund founded by an Elliott Management alumnus.
4:43 PMFinancial Times
Medical-aid-in-dying laws are expanding, giving more terminally ill people a legal path to end their lives under defined safeguards. Eligibility generally depends on meeting three conditions, including a qualifying terminal illness and the ability to make and carry out the decision.
12:56 PMMarketWatch
The roundup covers recent hires, departures, promotions and transfers across the pharmaceutical industry.
10:47 AMStat News
An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma, despite the agency having rejected it twice before.
9:28 AMStat News
The authors argue that the American Diabetes Association has moved away from the independence and courage it once displayed. They present the organization’s current conduct as a departure from that earlier standard.
4:30 AMStat News
The author says regulatory pathways designed to speed access to breakthrough treatments are sometimes being applied in ways that block approval instead. Patients with limb girdle muscular dystrophy are left navigating a system that promises faster access but can produce delay.
4:30 AMStat News
Syphilis is spreading in the San Diego-Tijuana border region as researchers face federal restrictions and a shortage of treatment. The overlapping public health and research obstacles complicate efforts to contain transmission.
4:30 AMStat News
The authors respond to an op-ed they say misrepresented their Covid study. They argue that assessing the U.S. pandemic response requires careful, rigorous, and honest interpretation of the evidence rather than revisionist claims.
4:30 AMStat News11:18 PMAl Jazeera
Liberia’s kush crisis: The hidden trade behind a generation at risk
Summary
Kush, a dangerous synthetic drug, is spreading across Liberia and leaving families to manage its social and health consequences. The people driving the trade remain largely beyond the reach of authorities.
The crisis is shifting the burden from traffickers to households and an already strained public
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Liberia’s kush epidemic shows how an illicit drug market can become a long-term public health crisis when enforcement and treatment fail to keep pace.
6:10 PMAl Jazeera
US Senate’s Fauci hearing renews COVID origin debate but reveals little
Summary
A Senate hearing featuring Anthony Fauci revived the dispute over COVID-19's origins but produced little new evidence. The session reflected the partisan divide surrounding the issue and the influence of misleading claims from the White House.
The hearing changed the political temperature more than the factual record. Without new evidence, the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The unresolved debate will continue to shape public trust in health agencies and future pandemic policy.
4:43 PMFinancial Times
KKR nears $4bn deal to buy medical device maker Integer Holdings
Summary
KKR is nearing an agreement worth more than $4 billion to acquire medical device maker Integer Holdings, which has also attracted attention from an activist hedge fund founded by an Elliott Management alumnus.
The potential deal would take Integer private and place its growth and operating strategy under
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The transaction signals continued private-equity appetite for medical device companies with opportunities to improve margins or consolidate operations.
12:56 PMMarketWatch
It’s getting easier for terminally ill people to end their own lives. What to know as laws change.
Summary
Medical-aid-in-dying laws are expanding, giving more terminally ill people a legal path to end their lives under defined safeguards. Eligibility generally depends on meeting three conditions, including a qualifying terminal illness and the ability to make and carry out the decision.
As more jurisdictions change their laws, access will depend increasingly on where patients live and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The policy shift is widening end-of-life options while creating uneven access and new legal and clinical obligations.
10:47 AMStat News
STAT+: Up and down the ladder: The latest comings and goings
Summary
The roundup covers recent hires, departures, promotions and transfers across the pharmaceutical industry.
The personnel moves provide a snapshot of where drugmakers are adding or changing leadership and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Leadership changes can reveal which therapeutic areas and business functions pharmaceutical companies consider most important.
9:28 AMStat News
STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
Summary
An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma, despite the agency having rejected it twice before.
The panel's support creates a new regulatory opening for Replimune after two FDA rejections, but
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A favorable advisory vote could revive a melanoma drug's prospects while testing how much influence the panel has over FDA decisions.
4:30 AMStat News
Opinion: We once praised the American Diabetes Association’s courage. How things have changed
Summary
The authors argue that the American Diabetes Association has moved away from the independence and courage it once displayed. They present the organization’s current conduct as a departure from that earlier standard.
The central shift is the authors’ judgment that the ADA no longer acts as a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A less independent diabetes advocacy group could weaken scrutiny of decisions affecting millions of patients.
4:30 AMStat News
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
Summary
The author says regulatory pathways designed to speed access to breakthrough treatments are sometimes being applied in ways that block approval instead. Patients with limb girdle muscular dystrophy are left navigating a system that promises faster access but can produce delay.
The decisive problem is a gap between the purpose of accelerated regulatory tools and their
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Regulatory failure in rare diseases can turn promising therapies into years of additional waiting for patients with limited time.
4:30 AMStat News
Syphilis spreads while researchers contend with federal constraints and a drug shortage
Summary
Syphilis is spreading in the San Diego-Tijuana border region as researchers face federal restrictions and a shortage of treatment. The overlapping public health and research obstacles complicate efforts to contain transmission.
The outbreak is colliding with two preventable constraints: limited access to a key drug and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A treatable infection becomes harder to control when medicine shortages and research barriers hit the same vulnerable region.
4:30 AMStat News
Opinion: What a recent op-ed got wrong about our Covid study
Summary
The authors respond to an op-ed they say misrepresented their Covid study. They argue that assessing the U.S. pandemic response requires careful, rigorous, and honest interpretation of the evidence rather than revisionist claims.
The immediate conflict is over how research findings should be used in the broader debate
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Disputes over Covid evidence still shape public trust in science and future pandemic policy.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!